Every material Form 8-K Stoke Therapeutics, Inc. has filed with the SEC since August 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Stoke Therapeutics reported third-quarter 2026 results, with revenue of $11.3 million, up from $10.6 million a year earlier, while its net loss widened to $73.6 million from $38.3 million as research and development and sales, general and administrative spending rose. The company said its $358.8 million in cash, cash equivalents and marketable securities is expected to fund operations into early 2028, and it still anticipates the Phase 3 EMPEROR data readout in the third quarter of 2027.
Q3 2026 revenue was $11.3 million, compared with $10.6 million in Q3 2025.
Q3 2026 net loss was $73.6 million, or $1.08 per share, versus $38.3 million, or $0.65 per share, a year earlier.
Research and development expenses rose to $59.8 million from $37.7 million, driven by zorevunersen advancement.
Cash, cash equivalents and marketable securities were $358.8 million as of September 30, 2026.
Stoke Therapeutics disclosed that Director Edward M. Kaye, M.D. resigned from the Board and its Research and Development Committee effective September 23, 2026, and that the company said the resignation was not due to any disagreement. The Board appointed Alexander (Bo) Cumbo as a Class III director the same day to fill the vacancy, a board change that is routine for shareholders.
Edward M. Kaye, M.D. resigned as Class III director and from the R&D Committee, effective September 23, 2026; the filing says no disagreement was involved.
Alexander (Bo) Cumbo appointed Class III director effective September 23, 2026, with a term expiring at the 2028 Annual Meeting.
Cumbo receives a $45,000 annual cash retainer and an initial stock option for 39,674 shares, valued at approximately $724,000 under ASC 718.
The Board determined Cumbo is independent under SEC and Nasdaq rules.
Stoke Therapeutics filed a prospectus supplement on August 3, 2026, covering the offer and sale of up to $200 million of common stock through Cantor Fitzgerald under an existing May 2022 sales agreement. The filing makes new share issuance possible, which could dilute existing shareholders, but the filing itself does not state how many shares have been sold or at what prices.
Prospectus supplement filed August 3, 2026 covers up to $200,000,000 of Placement Shares.
Sales run through Cantor Fitzgerald & Co. under the Controlled Equity Offering sales agreement dated May 20, 2022.
Offering is made under an automatic shelf registration statement (Form S-3ASR, File No. 333-294402) filed March 18, 2026.
Fenwick & West LLP legal opinion is filed as Exhibit 5.1.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Stoke Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →